Empresas y finanzas

BIOIDENT Wins Illustrious 2007 Wall Street Journal Technology Innovation Awards



    BIOIDENT Technologies Inc., the leading company in the development
    of printed opto-electronic solutions for life sciences, today
    announced that the company is a co-winner in the semiconductor
    category for the seventh annual Wall Street Journal contest for
    Technology Innovation. BIOIDENT was awarded for the development of its
    PhotonicLab Platform(TM), which enables rapid in-vitro diagnostics,
    chemical and biological threat detection, and environmental testing
    without the need for off-site lab analysis.

    "We are delighted to win this prestigious award that recognizes
    our innovative work on the cutting edge of nanotechnology," said Dr.
    Wasiq Bokhari, CEO for BIOIDENT. "Once again, BIOIDENT is being
    acknowledged as the pioneer in applying its unique printed
    opto-electronics to real-world applications. We will continue to
    leverage our unique technology to develop new solutions to address
    major industry challenges."

    Utilizing the latest breakthroughs in science and nanotechnology,
    the BIOIDENT PhotonicLab Platform is used to produce the world's first
    disposable photonic lab-on-a-chip solution for next-generation mobile
    analytics applications, such as water and food analysis, chemical and
    biological agent detection, and point-of-care diagnostics. BIOIDENT
    employs a process developed by its parent company, Austria's NANOIDENT
    Technologies AG, for using an inkjet printer to print electronic
    circuits on a variety of surfaces, such as plastic foil or glass; the
    technology makes it possible to apply photosensitive semiconductors
    directly onto a lab-on-a-chip. The Platform eliminates the need for
    complex and expensive readout systems and delivers unprecedented
    mobility and sensitivity based on existing biological and chemical
    assays.

    About The Wall Street Journal Technology Innovation Awards

    As part of the 2007 award nomination process, The Wall Street
    Journal screened more than 800 applications, narrowing the field to
    about 150 entries. A panel of 13 judges picked category winners and
    runners-up in 12 different entry categories including computing
    systems, energy, environment, materials and other base technologies,
    media/broadcasting, medical research, medical devices,
    network/internet technologies, network security, semiconductors,
    software and transport. Each entrant was required to offer extensive
    details and explain why the entry merited consideration. Judging
    criteria included innovativeness, clarity of explanation, whether the
    innovation was covered by patents and if it had achieved some measure
    of success. Factors the panel considered included: the innovation
    should have gone well beyond what already existed and cannot simply
    represent incremental improvements; it needed to address major
    challenges for which new solutions would have a wide-ranging impact in
    a particular industry; the written application needed to be supported
    by rigorous data rather than unsubstantiated claims of potential.

    About BIOIDENT Technologies Inc.

    BIOIDENT is the leader in the development of rapid, multi-assay
    and mobile analytical and diagnostic systems. BIOIDENT integrates
    highly sensitive printed photodetectors and electronics with various
    existing Lab-on-a-Chip (LOC) technologies including lateral flow,
    microfluidics and microarrays. BIOIDENT's systems are designed for
    applications in in-vitro diagnostics, chemical and biological threat
    detection, and environmental testing. BIOIDENT's award-winning
    Photonic Lab(TM) Technology Platform eliminates the need for complex
    and expensive readout systems and delivers unprecedented mobility and
    sensitivity based on existing biological and chemical assays. Benefits
    for BIOIDENT's customers and partners include high mobility, rapid
    testing, multiplexing and low cost of ownership.

    BIOIDENT is a subsidiary of Austrian-based NANOIDENT Technologies
    AG, the world leader in printed opto-electronics. The company is
    privately held with headquarters in Menlo Park, California. BIOIDENT
    leverages NANOIDENT's SEMICONDUCTOR 2.0(TM) Platform technology and
    its high-speed manufacturing process, which uses liquid conductive and
    semi-conductive materials to print electronic circuits on almost any
    surface using an inkjet printer. NANOIDENT also has the world's only
    dedicated organic fabrication facility with a production output of
    40,000 sq.m per year. For more information about the company, please
    visit www.bioident.com.